Learn the Science Behind This Tool
Drugs in the News for Lung Cancer Treatment
The treatment of advanced lung cancer has greatly benefited by approval of targeted therapies in the past few years. Newer targeted therapies, such as Crizotinib, are in clinical trials for lung cancer and promise to benefit even more lung cancer patients. These advances are also driving personalization of treatments for lung cancer patients based on their tumors’ molecular fingerprint.
| Drug | Other names | Target | Manufacturer | Status |
|---|---|---|---|---|
| Afatinib | Tomtovok, BIBW2992 | Boehringer Ingelheim | In phase 3 clinical trials for NSCLC and phase 2 clinical trials for various cancers including: breast cancer, glioma, and colorectal cancer | |
| Avastin | bevacizumab | Genentech/Roche | Approved for the first-line treatment of metastatic Non-Small Lung Cancer (NSCLC). In phase 1 or 2 clinical trials for numerous cancers including: Glioblastoma, liver cancer, rectal cancer, ovarian carcinoma | |
| Tarceva | Erlotinib | Genentech, OSI Pharmaceuticals, Roche | Approved for NSCLC, pacreatic cancer, and several other cancers. | |
| Xalkori | crizotinib, PF-02341066 | Pfizer | Approved for NSCLC; in clinical trials for combination therapies |
This list features only some of the drugs discussed in the Therapy Finder. Find drugs that may be relevant to you by providing information about your lung cancer on the home page.